Strawbridge Rebecca, Jamieson Alzbeta, Hodsoll John, Ferrier Ian Nicol, McAllister-Williams Richard Hamish, Powell Timothy R, Young Allan H, Cleare Anthony J, Watson Stuart
Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, PO74, King's College London, De Crespigny Park, London SE5 8AZ, UK.
National Institute for Health Research Maudsley Biomedical Research Centre, South London & Maudsley NHS Foundation Trust, London SE5 8AZ, UK.
J Clin Med. 2021 Feb 16;10(4):784. doi: 10.3390/jcm10040784.
Optimising treatments for patients with treatment-resistant depression (TRD) is key to reducing the burden of this severe illness. The anti-glucocorticoid medication metyrapone has mixed evidence supporting a role as a possible augmentation treatment in TRD. The degree of treatment resistance in depression has been associated prospectively and retrospectively with elevated inflammation, and inflammatory activity may influence responses to antidepressant treatments.
To investigate whether levels of pro-inflammatory cytokines are associated with clinical outcomes to metyrapone or placebo.
A double-blind RCT randomised patients with TRD to 3 weeks of placebo or metyrapone augmentation to ongoing serotonergic antidepressants. No benefit of metyrapone was reported in the primary analysis. The current study assessed levels of pro-inflammatory proteins interleukin-6 (IL-6), tumour necrosis factor (TNFα), c-reactive protein (CRP) and interleukin-10 (IL-10) before randomisation and after treatment as potential moderators and/or mediators of clinical outcomes.
The three pro-inflammatory proteins (but not IL-10) were elevated in this sample of patients with TRD compared to a non-affected control group. High pre-treatment IL-6 levels predicted a poorer response in the trial overall but did not moderate response to metyrapone versus placebo. Changes in IL-6 indirectly mediated depression outcome, with metyrapone increasing IL-6 levels and IL-6 increase associated with a poorer outcome on depression. Other inflammatory proteins did not mediate or moderate treatment outcomes.
Metyrapone is hypothesised to have a therapeutic effect in depression on the basis of inhibiting the synthesis of cortisol. In this study, metyrapone did not reduce cortisol, possibly due to glucocorticoid system overcompensation). The mediation effect of IL-6 may support this and perhaps help to indicate why the treatment was not effective.
优化难治性抑郁症(TRD)患者的治疗方法是减轻这种严重疾病负担的关键。抗糖皮质激素药物甲吡酮有一些证据支持其作为TRD可能的增效治疗方法,但证据并不一致。抑郁症的治疗抵抗程度在前瞻性和回顾性研究中均与炎症升高有关,且炎症活动可能影响对抗抑郁治疗的反应。
研究促炎细胞因子水平是否与甲吡酮或安慰剂的临床疗效相关。
一项双盲随机对照试验将TRD患者随机分为两组,一组接受3周的安慰剂治疗,另一组在持续使用血清素能抗抑郁药的基础上加用甲吡酮进行增效治疗。在初步分析中未报告甲吡酮有任何益处。本研究评估了随机分组前和治疗后的促炎蛋白白细胞介素-6(IL-6)、肿瘤坏死因子(TNFα)、C反应蛋白(CRP)和白细胞介素-10(IL-10)水平,将其作为临床疗效的潜在调节因子和/或介导因子。
与未受影响的对照组相比,该TRD患者样本中的三种促炎蛋白(但不包括IL-10)水平升高。治疗前IL-6水平较高预示着试验总体反应较差,但对甲吡酮与安慰剂的反应没有调节作用。IL-6的变化间接介导了抑郁结局,甲吡酮会升高IL-6水平,而IL-6升高与抑郁结局较差相关。其他炎症蛋白未介导或调节治疗结局。
基于抑制皮质醇合成的作用,甲吡酮被推测对抑郁症有治疗效果。在本研究中,甲吡酮未能降低皮质醇水平,可能是由于糖皮质激素系统的过度代偿。IL-6的介导作用可能支持这一观点,或许有助于解释为何该治疗无效。